Table 5. BEVACIZUMAB IN OVARIAN CANCER: Phase III Trial - Clinical Trials Ongoing.

ClinicalTrials.gov Identifier	Responsible Party	Detailed Description	Regimen
NCT01802749	National Cancer Institute, Naples	Second-line treatment in platinum sensitive EOC pts after a BV/CT First-line	Arm-1: PLD+Cb±BV Arm-2: Gem+Cb±BV Arm-3: P+Cb±BV
NCT01837251	AGO Research GmbH	Platinum-sensitive recurrent EOC pts	Arm-1: BV→Gem+Cb (6 cycles)→BV Arm-2: BV→PLD+Cb (6 cycles)→BV
NCT01081262	National Cancer Institute, US	Stage II-IV, or recurrent stage I EOC or FTC pts	Arm-1: Cb+P (6 cycles) Arm-2: Oxa+Cape (6 cycles) Arm-3: Cb+P+BV (6 cycles)→ BV (12 cycles) Arm-4: Oxa+Cape (6 cycles)→ BV (12 cycles)
NCT01239732	Hoffmann-La Roche	Front-line treatment of pts with EOC, FTC or PPC	P (8 cycles)+BV (36 cycles)+Cb (4-8cycles)
NCT01462890	AGO Study Group	First-line treatment of EOC, FTC or PPC	Arm-1: CB+P+BV (6 cycles)→ BV (16 cycles) Arm-2: CB+P+BV (6 cycles)→ BV (38 cycles)
NCT00951496	National Cancer Institute, US	EOC, PP or FTC at stage II, III, or IV with either optimal or suboptimal residual disease	Arm-1: Cb+P [6 cycles]+BV(cycles 2-22) Arm-2: P+Cb(IP) [6 cycles]+BV (cycles 2-22) Arm-3: P-Cis(IP) [6 cycles]+BV (cycles 2-22)
NCT00565851	National Cancer Institute, US	Platinum-sensitive, recurrent EOC, PPC or FTC	Arm-1: Cb+D/P Arm-2: Cb+D/P+BV Arm-3: Cb+Gem Arm-4: Cb+Gem+BV

Reference: https://clinicaltrials.gov/; Abbreviations: Cb= carboplatin; P= paclitaxel; D= docetaxel; Gem= gemcitabine; BV= bevacizumab; Erl= erlotinib; Tem= temsirolimus; Ixa= ixabepilone; Eve= everolimus; Let= letrozole; Top= topotecan; Tam= tamoxifen; Rida= ridaforolimus; Nir= niraparib; Mel= melphalan; Rev= revlimid; Dox= doxil; Vel= Veliparib; Pem= Pemetrexed; Cis= cisplatin; IV= intravenous; IP= intraperitoneal; →= followed by; SD= stable disease; PD= disease progression; PPC= Primary Peritoneal Carcinoma; FTC= Fallopian Tube Cancer; Fos= fosbretabulin-tromethamine; MSKCC= Memorial Sloan Kettering Cancer Center;